Emerald Advisers INC Boosted Its Stake in Puma Biotechnology INC (PBYI) as Valuation Declined

March 18, 2018 - By Darrin Black

Investors sentiment increased to 1.55 in 2017 Q3. Its up 0.34, from 1.21 in 2017Q2. It increased, as 19 investors sold PBYI shares while 41 reduced holdings. 41 funds opened positions while 52 raised stakes. 35.70 million shares or 3.15% more from 34.61 million shares in 2017Q2 were reported. Bancshares Of Mellon holds 0.01% or 182,298 shares. 15,987 were accumulated by Highland Mgmt Limited Partnership. State Of New Jersey Common Pension Fund D holds 0.01% or 25,833 shares in its portfolio. Jane Street Group Ltd Liability stated it has 0.01% of its portfolio in Puma Biotechnology, Inc. (NASDAQ:PBYI). Hbk Invs Lp invested in 0.05% or 55,058 shares. Orbimed Advsrs Limited Co, New York-based fund reported 2.43M shares. Quantitative Investment Ltd Liability Com holds 0.04% or 30,000 shares. Huntington Fincl Bank owns 100 shares. Ghost Tree Cap Ltd Com has invested 1.65% in Puma Biotechnology, Inc. (NASDAQ:PBYI). Strs Ohio accumulated 0% or 2,700 shares. Morgan Stanley accumulated 59,351 shares. Qs Invsts Limited Liability Co owns 1,000 shares. Rice Hall James And Assocs Limited Liability Corporation invested 0.12% of its portfolio in Puma Biotechnology, Inc. (NASDAQ:PBYI). Tekla Cap Mgmt Lc reported 105,495 shares or 0.45% of all its holdings. Blackrock Inc accumulated 1.81 million shares or 0.01% of the stock.

Since September 29, 2017, it had 0 insider purchases, and 5 insider sales for $3.20 million activity. Lo Steven also sold $172,515 worth of Puma Biotechnology, Inc. (NASDAQ:PBYI) shares. 15,000 shares were sold by BRYCE RICHARD PAUL, worth $1.80M. 10,692 shares valued at $991,683 were sold by AUERBACH ALAN H on Monday, January 22.

Emerald Advisers Inc increased its stake in Puma Biotechnology Inc (PBYI) by 16.48% based on its latest 2017Q3 regulatory filing with the SEC. Emerald Advisers Inc bought 52,355 shares as the company’s stock declined 6.09% while stock markets rallied. The institutional investor held 370,035 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $44.31 million, up from 317,680 at the end of the previous reported quarter. Emerald Advisers Inc who had been investing in Puma Biotechnology Inc for a number of months, seems to be bullish on the $ market cap company. It closed at $0 lastly. It is down 23.65% since March 18, 2017 and is uptrending. It has outperformed by 6.95% the S&P500.

Emerald Advisers Inc, which manages about $1.71B and $2.46 billion US Long portfolio, decreased its stake in Dycom Industries Inc (NYSE:DY) by 153,747 shares to 279,952 shares, valued at $24.04M in 2017Q3, according to the filing. It also reduced its holding in Oclaro Inc (NASDAQ:OCLR) by 574,482 shares in the quarter, leaving it with 1.28M shares, and cut its stake in Vonage Holdings Corp (NYSE:VG).

More news for Puma Biotechnology, Inc. (NASDAQ:PBYI) were recently published by: Businesswire.com, which released: “Puma Biotechnology Receives Results of CHMP Formal Decision for Neratinib for …” on February 23, 2018. Businesswire.com‘s article titled: “Puma Biotechnology to Present at Cowen’s Annual Healthcare Conference” and published on March 06, 2018 is yet another important article.

Puma Biotechnology, Inc. (NASDAQ:PBYI) Ratings Coverage

Among 11 analysts covering Puma Biotechnology Inc (NYSE:PBYI), 9 have Buy rating, 0 Sell and 2 Hold. Therefore 82% are positive. Puma Biotechnology Inc has $164 highest and $36 lowest target. $100.55’s average target is 0.00% above currents $0 stock price. Puma Biotechnology Inc had 60 analyst reports since August 27, 2015 according to SRatingsIntel. RBC Capital Markets maintained it with “Sector Perform” rating and $60 target in Thursday, May 25 report. RBC Capital Markets maintained it with “Hold” rating and $92.0 target in Wednesday, October 25 report. The firm has “Buy” rating given on Tuesday, March 29 by Citigroup. UBS maintained the shares of PBYI in report on Monday, April 11 with “Buy” rating. Bank of America maintained the stock with “Buy” rating in Monday, October 9 report. The firm earned “Overweight” rating on Friday, November 10 by Barclays Capital. The stock of Puma Biotechnology, Inc. (NASDAQ:PBYI) earned “Buy” rating by Stifel Nicolaus on Wednesday, August 9. The rating was downgraded by RBC Capital Markets on Tuesday, March 29 to “Sector Perform”. The rating was maintained by Leerink Swann with “Outperform” on Monday, July 10. The rating was maintained by Credit Suisse on Tuesday, March 29 with “Outperform”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.